Current Insight into the Role of IL-35 and Its Potential Involvement in the Pathogenesis and Therapy of Atopic Dermatitis

Int J Mol Sci. 2022 Dec 11;23(24):15709. doi: 10.3390/ijms232415709.

Abstract

Interleukin 35 (IL-35), a new member of the IL-12 family of heterodimeric cytokines, could induce two different types of regulatory cells including regulatory T and B cells such as IL-35-induced regulatory T cells and IL-10-producing regulatory B cells (IL-10+Bregs), and IL-35-producing regulatory B cells (IL-35+Bregs). These cells appear to play an important role in modulating the immune system in numerous diseases. Several findings suggested that the expression of IL-35 is dysregulated in many autoimmune, inflammatory, and allergic diseases. Due to the functions of IL-35, it seems that this cytokine may act as an efficient therapeutic strategy for numerous conditions including atopic dermatitis (AD). We aimed to provide a comprehensive overview of the role of IL-35 in modulating the immune system. Additionally, we highlight IL-35 as a specific immunological target, discuss its possible involvement in the pathogenesis of AD, and hypothesize that IL-35 may become a novel target for the treatment of AD. However, further studies are required to evaluate this hypothesis.

Keywords: Interleukin 35; atopic dermatitis; iTr35 cells; immunological disturbances; regulatory B cell; regulatory T cell.

Publication types

  • Review

MeSH terms

  • Cytokines / metabolism
  • Dermatitis, Atopic* / drug therapy
  • Humans
  • Interleukin-10
  • Interleukins* / metabolism
  • T-Lymphocytes, Regulatory

Substances

  • Cytokines
  • Interleukin-10
  • interleukin-35, human
  • Interleukins

Grants and funding

This research received no external funding.